all report title image
  • Published On : Sep 2022
  • Code : CMI5242
  • Industry : Pharmaceutical
  • Pages : 197
  • Formats :

Bovine Tuberculosis (TB) is an infectious disease of cattle. It is caused by the bacterium Mycobacterium bovis (M. bovis), which can also infect and cause disease in several other mammals including humans, deer, goats, pigs, cats, dogs, and badgers. In cattle, it is mainly a respiratory disease but clinical signs are rare. The prototype vaccination for domestic livestock and wildlife was Bacille Calmette-Guérin (BCG). The Bacillus of Calmette and Guerin (BCG) strain of mycobacterium bovis is used in the BCG vaccine for percutaneous application. It is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. The TICE (Bacillus of Calmette and Guerin) strain, which is used in this BCG vaccine formulation, was created at the University of Illinois from a Pasteur Institute.

Global veterinary tuberculosis vaccine market is estimated to be valued at US$ 50.89 Mn in 2022 and is expected to exhibit a CAGR of 3.2% over the forecast period (2022-2030).

Figure 1: Global Veterinary Tuberculosis Vaccine Market Share (%) Analysis, By Product Type, 2022

Veterinary Tuberculosis Vaccine  | Coherent Market Insights

Increasing government initiative for veterinary tuberculosis vaccine is expected propel the global veterinary tuberculosis vaccine market growth over the forecast period.

Increasing government initiative for veterinary tuberculosis vaccine is expected propel the global veterinary tuberculosis vaccine market growth over the forecast period. For instance, on July 22, 2020, the Department for Environment, Food & Rural Affairs and Animal and Plant Health Agency, U.K, had given permission to scientists from U.K. government research organization to conduct field trial for bovine tuberculosis (bTB) TB cattle vaccination.  These field trials would be conducted over the next four years from 2021 till 2024 on behalf of Defra, the Welsh Government and the Scottish Government, following of ground-breaking research into bovine TB vaccines and diagnostic tests.

Increasing research and development for tuberculosis vaccine is expected to drive the global veterinary tuberculosis vaccine market growth over the forecast period.

Increasing research and development for tuberculosis vaccine is expected to drive the global veterinary tuberculosis vaccine market growth over the forecast period. For instance, on  November 28, 2019, an article was published by the University of Surrey about the research for new vaccine developed for treating bovine tuberculosis (bovine TB) in form of a novel vaccine and complementary skin test to protect cattle. The scientific study has been published for novel vaccine and complementary skin test to protect cattle. The protective efficiency of the new strain was tested in guinea pigs.

CMI table icon

Veterinary Tuberculosis Vaccine Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 50.89 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 3.2% 2030 Value Projection: US$ 65.36 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Live Attenuated, Inactivated
  • By Route of Administration: Sub-cutaneous, Intramuscular, Oral
  • By Animal Type: Cattle, Dogs, Cats, Others
Companies covered:

Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc.

Growth Drivers:
  • Increasing government initiatives for veterinary tuberculosis vaccine
  • Increasing research and development for tuberculosis vaccine
Restraints & Challenges:
  • Discontinuation of animal vaccine

Global Veterinary Tuberculosis Vaccine Market- Impact of the Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

The current pandemic of COVID-19 has set off an urgent search for an effective vaccine. This search may well benefit from the experiences of the animal health profession in the development and use of coronavirus vaccines in domestic animal species. According to an article published on July 14, 2020 by the National Center for Biotechnology Information (NCBI) stated about new developed vaccine for animal species, where two types of vaccine have been developed against alphacoronaviru (CCoV) such as inactivated and live-attenuated vaccination for dogs with an inactivated CCoV vaccine reduced the level of viral shedding in the feces and was effective following experimental challenge in dogs. Thus, 15% of vaccinated dogs developed mild symptoms while 80% of unvaccinated dogs developed disease symptoms and 60% eventually developed severe symptoms.

Global Veterinary Tuberculosis Vaccine Market– Restraints

Discontinuation of animal vaccine is expected to hamper growth of the global veterinary tuberculosis vaccine market over the forecast period.

For instance, on April 16, 2019, Wisconsin Department of Agriculture announced that Boehringer Ingelheim, an animal healthcare company discontinued Mycopar, a vaccine used in Johne’s disease in herd. Mycopar is currently the only Johne’s vaccine licensed in the U.S. As a result, veterinarians would need to advise herd owners using the vaccine that the product would no longer be one of the tools available to manage Johne’s disease in Wisconsin.

Global Veterinary Tuberculosis Vaccine Market– Regional Analysis

On the basis of region, the Global Veterinary Tuberculosis Vaccine Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Asia Pacific market is expected to witness significant growth, owing to key companies in market focusing on adopting inorganic strategies such as agreements with other market players. Bovine tuberculosis (bTB) is common is Asia. A significant prevalence of bTB in the region is expected to drive the market growth. For instance, according to an article published in 2018 in Transboundary and Emerging Disease, in 2017, the prevalence of bTB in India was 7.3%.However, according to the World Animal Health Information System, bovine TB is found in most parts of Asia. However, most of the pacific island countries such as Micronesia, New Caledonia, and Papua New Guinea have never reported this disease. In addition, in Australia, bTB has successfully been eradicated from cattle. The last known cases of bTB in Australia were detected in 2002. Several countries such as Japan, Mongolia, Myanmar, Singapore, and Thailand have successfully reduced bovine TB from their cattle population.

Figure 2: Global Veterinary Tuberculosis Vaccine Market Value (US$ Bn), by Region, 2022

Veterinary Tuberculosis Vaccine  | Coherent Market Insights

Global Veterinary Tuberculosis Vaccine Market– Competitive Landscape

Major players operating in the global veterinary tuberculosis vaccine market include Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc.

Tuberculosis (TB) is considered a reemerging, infectious granulomatous disease in animals and people caused by acid-fast bacilli of the genus Mycobacterium. Although commonly considered as a chronic, debilitating disease, TB occasionally assumes an acute, rapidly progressive course. The disease affects practically all species of vertebrates. The widespread occurrence of multidrug-resistant (MDR) strains and extensively drug-resistant (XDR) strains of M tuberculosis is of concern to clinicians and public health and regulatory officials involved in the control of the disease. Bovine TB is still a significant zoonosis in non-industrialized countries of the world. Signs and lesions are generally similar in the various species. The main types of M tuberculosis complex (mammalian tubercle bacilli) recognized are M tuberculosis, M canettii, M bovis, M caprae, M pinnipedii, M microti, M mungi, and M africanum. The M avium complex includes M avium avium (avian tubercle bacilli), M avium hominissuis (isolated from people, swine, and other mammals), and M intracellular.

Market Dynamics

Increasing undergoing trial for vaccination is expected to fuel growth of the global veterinary tuberculosis vaccine market over the forecast period.

For instance, according to a report published by Multidisciplinary Digital Publishing Institute in June 2020, BCG (Danish) vaccine type is administered by intramuscular to badgers for the prevention of tuberculosis. According to the same source, heat-inactivated Mycobacterium bovis vaccine (HIMB) is administered by intramuscular method to goats for the prevention of tuberculosis

Furthermore, increasing awareness programs for veterinary tuberculosis by government authorities is expected to drive growth of the global veterinary tuberculosis vaccine market over the forecast period.

For instance, on November 16, 2021, The Welsh Government, U.K. announced the Tuberculosis (TB) Eradication Programme. This program's goal was to offer a TB testing programme in Wales, U.K., in order to further lower the danger of the spread of TB. The Welsh Government, U.K. has advised to make informed purchase selections and to disclose TB information about any cattle they seek to sell. Payments for animals that were killed due to TB, to make sure the method is just and appropriate and takes into account the available funding.

Key features of the study:

  • This report provides an in-depth analysis of the global veterinary tuberculosis vaccine market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global veterinary tuberculosis vaccine market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global veterinary tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global veterinary tuberculosis vaccine market

Detailed Segmentation:

  • Global Veterinary tuberculosis vaccine market, By Type:
    • Live Attenuated
    • Inactivated
  • Global Veterinary tuberculosis vaccine market, By Route of Administration:
    • Sub-cutaneous
    • Intramuscular
    • Oral
  • Global Veterinary tuberculosis vaccine market, By Animal Type:
    • Cattle
    • Dogs
    • Cats
    • Others
  • Global Veterinary tuberculosis vaccine market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Merck KGaA *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Colorado Serum Company
    • CZ Vaccines (Zendal)
    • Zoetis Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global veterinary tuberculosis vaccine market is expected to exhibit a CAGR of 3.2% during the forecast period (2022-2030).
The market is estimated to be valued at US$ 50.89 Mn in 2022.
Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc. are some of the prominent players operating in the market.
The market is expected to be valued at US$ 65.36 Mn in 2030.
Asia Pacific is the prominent region in the market.
Live Attenuated, which belongs to the type segment, is the prominent segment in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo